Literature DB >> 8238371

GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery.

G Richter1, O Feddersen, U Wagner, P Barth, R Göke, B Göke.   

Abstract

Recent data revealed the existence of specific receptors for glucagon-like peptide-1(7-36)amide (GLP-1) on rat lung membranes. Utilizing slide-mount autoradiography of fresh frozen lung tissue sections, we have localized binding sites for GLP-1 on mucous glands in the trachea and on vascular smooth muscle of the pulmonary artery. When tracheas were incubated in a modified Ussing chamber, the addition of GLP-1 to the submucosal side increased 35S-sulfate-labeled macromolecule secretion (191 +/- 12% above basal, P < 0.005). The optimal secretory response elicited by GLP-1 was approximately 23% of the maximal secretory response after a maximal acetylcholine stimulation. Other proglucagon-derived peptides such as glucagon, oxyntomodulin, and GLP-2 had no effect. In isolated rings of arteries, GLP-1 (10(-8) to 10(-5) M) induced a dose-dependent and time-reversible relaxation of preconstricted arteries. In a preparation with denuded epithelium, GLP-1 lost its effect. In conclusion, GLP-1 might represent another neuropeptide that acts as neurotransmitter of the peptidergic, nonadrenergic-noncholinergic nervous system that innervates the airways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238371     DOI: 10.1152/ajplung.1993.265.4.L374

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  50 in total

Review 1.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 2.  Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Authors:  Mauro Cataldi; Angelo Cignarelli; Francesco Giallauria; Giovanna Muscogiuri; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 3.  The role of endothelial insulin signaling in the regulation of glucose metabolism.

Authors:  Tetsuya Kubota; Naoto Kubota; Takashi Kadowaki
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 4.  Cardiovascular effects of incretin-based therapies.

Authors:  Michael Lehrke; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2014-08       Impact factor: 6.124

7.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

8.  Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Authors:  Thomas Jax
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

9.  Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes.

Authors:  Juraj Koska; Eric A Schwartz; Michael P Mullin; Dawn C Schwenke; Peter D Reaven
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

10.  Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

Authors:  Masayuki Arakawa; Tomoya Mita; Kosuke Azuma; Chie Ebato; Hiromasa Goto; Takashi Nomiyama; Yoshio Fujitani; Takahisa Hirose; Ryuzo Kawamori; Hirotaka Watada
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.